Xeris Biopharma Holdings, Inc. (XERS) 8-K Current Report — March 2, 2026

Filed: March 2, 2026

Health Care

Pharmaceutical Preparations

Xeris Biopharma Holdings, Inc. (XERS) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 2.02: Results of Operations and Financial Condition

Xeris Biopharma Holdings, Inc. 8-K Mar 2, 2026 Event Analysis

Item 2.02 · Results of Operations and Financial Condition

• Q4 and full-year 2025 earnings results released March 2, 2026 — details in Exhibit 99.1
• Covers periods ending December 31, 2025 (Q4 and FY2025)

Other Xeris Biopharma Holdings, Inc. 8-K Filings

8-K Feb 27, 2026

Get deeper insights on Xeris Biopharma Holdings, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.